MiNK Therapeutics (INKT) Q2 FY26 earnings call

MiNK Therapeutics advanced its lead asset, Agent 797, by initiating a randomized Phase 2 study for acute lung injury and ARDS and establishing an international paid patient access program in Brazil. The company reported initial positive observations from early ARDS patients and maintained financial discipline while preparing for US site activation and a potential seamless Phase 3 study. This quarter underscored the company's strategy of rigorous clinical development, rapid off-the-shelf cell therapy delivery, and responsible patient access.